Navigation Links
OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced today that the results of its Phase II combretastatin A4 phosphate (CA4P) clinical trial in myopic macular degeneration (MMD) was presented at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL. The abstract may be viewed at www.arvo.org.

The following are the poster session details: -0-

Poster No.:   1457/B534

Abstract      Phase II Clinical Trial of Intravenous Combretastatin A4

 Title:        Phosphate in Patients With Subfoveal Choroidal

               Neovascular Membranes (CNV) in Pathologic Myopia

Presentation  Monday, May 07, 2007, 8:30 AM -10:15 AM

 Time:

The poster provided additional details from the ZYBRESTAT(TM) CA4P Phase II clinical trial (MMD-213) in Myopic Macular Degeneration, top-line results from which the Company previously announced on February 15, 2007. Based on the positive results from this study, in which 100% of patients met the primary endpoint of maintenance of visual acuity, the Company has held a pre-IND meeting with the FDA regarding topical ophthalmic formulations (eye drops and ocular mini-tabs), is proceeding with development of a topical formulation of ZYBRESTAT(TM), and anticipates filing and IND and initiating clinical studies with the formulation in early 2008.

About the Study (MMD-213):

MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P for treating subfoveal choroidal neovascularization in subjects with pathologic myopia. Subjects were assigned to receive CA4P at doses of 27, 36 or 45 mg/m(2). A total of 23 subjects, 7-8 per arm, were enrolled. All subjects receive d active treatment; however, subjects and investigators were masked to dose. Subjects received two doses of CA4P one week apart with up to 3 additional doses and they were followed for 3 months for efficacy and safety. The primary efficacy variable was the best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual function (visual acuity). Secondary variables included fluorescein angiography and optical coherence tomography (OCT). All efficacy variables were evaluated by a masked grader. Safety was assessed via vital signs, laboratory tests, slit-lamp biomicroscopy, dilated fundus examination, fundus photography, serial ECGs and elicited and observed adverse events. Informal data reviews were conducted by OXiGENE throughout the trial to ensure patient safety.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's Form 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no oblig ation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2005 for a description of these risks.

NOTE TO EDITORS: In the expression, mg/m(2), which appears in the paragraph, About the Study (MMD-213):, the figure '2' is in superscript. This feature may not appear properly in some systems.

Contact

OXiGENE, Inc.
Investor Relations
781-547-5900


'"/>




Related medicine technology :

1. OXiGENE Abstracts Published in ASCO Program
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the leading provider of ... today the launch of a redesigned corporate website, 800response.com . , ... design, and an enhanced search directory for businesses and advertising agencies to use ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the Bible”: ... reflect upon the stories and the relevance these tales may have on the reader’s ... Linhart, a former special education teacher, Jessica spends much of her time enjoying nature ...
(Date:8/18/2017)... ... ... “Case #10-5411 Veterans Administration”: a personal account of corruption ... Administration” is the creation of published author, Carol Mulhern, single mother of two ... work at the Coatesville VAMC as a file clerk then later became the ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking forum of the ... Center at Harvard Medical School. , Industry leaders and decision makers will discuss ...
(Date:8/17/2017)... ... August 17, 2017 , ... Elemental LED, a leading U.S. ... Diode LED products were honored with Architectural SSL Product Innovation Awards ... its manufacturing and wholesale division, Diode LED, provides a wide variety of superior quality ...
Breaking Medicine News(10 mins):